The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.

@article{Bellmunt2009TheMM,
  title={The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.},
  author={Joaquim Bellmunt and Marta Guix},
  journal={BJU international},
  year={2009},
  volume={103 5},
  pages={572-7}
}
There are now five targeted agents, i.e. sorafenib, sunitinib, temsirolimus, bevacizumab (in combination with interferon) and everolimus, that have been shown to improve the outcome in patients with metastatic clear cell renal cell carcinoma (mRCC), in randomized controlled trials (RCTs). Compared with the period when cytokines were the only systemic intervention known to have any activity, decisions on medical management are now complex. Clinicians must seek to adjust therapy to the… CONTINUE READING
18 Extracted Citations
26 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 18 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 26 references

ASCO Genitourinary Cancers

  • TJ Smith, BE Hillner
  • 2008

CALGB 90206 . A Phase III trial of bevacizumab plus interferonalpha versus interferonalpha monotherapy in metastatic renal cell carcinoma

  • BI Rini, S Halabi, JE Rosenberg
  • ASCO Genitourinary Cancers Symposium
  • 2008

Cell Carcinoma: What Really Matters? Presented at the American Society of Clinical Oncology

  • Rini BI.Renal
  • Annual Meeting
  • 2008

Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma : subgroup analysis of The Approaches in Renal Cancer Global Evaluation Trial ( TARGETs )

  • T Eisen, S Oudard
  • Renal Cell Carcinoma : What Really Matters…
  • 2008

Similar Papers

Loading similar papers…